Naureen Ali, MD
Internal Medicine · Sullivan, MONPI 1487036547
Payments from drug & device makers
Across 212 payments — averaging $17.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$375
- AbbVie$342
- Novo Nordisk$311
- GSK$283
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$212
- Johnson & Johnson$206
- plus $2K from 28 others
What the payments were for
- Food & beverage$3,54998%
- Education$852%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 20 | $375 |
| AbbVie | 20 | $342 |
| Novo Nordisk | 17 | $311 |
| GSK | 22 | $283 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $212 |
| Johnson & Johnson(2 entities) | 11 | $206 |
| Merck | 14 | $190 |
| Amgen | 9 | $152 |
| Astellas Pharma US Inc | 4 | $141 |
| Exact Sciences | 7 | $125 |
| Dexcom, Inc. | 6 | $111 |
| Novartis | 7 | $109 |
| Organogenesis Inc. | 4 | $108 |
| Lundbeck LLC | 5 | $94 |
| Edwards Lifesciences | 4 | $88 |
| Bayer | 5 | $83 |
| AstraZeneca | 5 | $83 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $81 |
| Otsuka America Pharmaceutical, Inc. | 3 | $58 |
| Sanofi-aventis U.S. LLC | 3 | $53 |
| Sumitomo Pharma America, Inc. | 3 | $47 |
| Sobi, Inc | 2 | $42 |
| Pfizer | 3 | $41 |
| Kowa Pharmaceuticals America, Inc. | 2 | $40 |
| Bristol Myers Squibb | 2 | $40 |
| Gilead | 2 | $33 |
| Valinor Pharma, LLC | 2 | $30 |
| Exeltis, USA Inc. | 2 | $30 |
| Phathom Pharmaceuticals, Inc. | 2 | $27 |
| Xeris Pharmaceuticals, Inc. | 1 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| Shield Therapeutics Inc | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $15 |
How this compares
$3,634 in reported general payments places this provider in the 85th percentile of 2,097 internal medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 17 | $78,400 |
| MounjaroTirzepatide | 53 | $70,024 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 93 | $68,509 |
| OzempicSemaglutide | 53 | $63,465 |
| JardianceEmpagliflozin | 71 | $57,359 |
| EliquisApixaban | 26 | $32,320 |
| FarxigaDapagliflozin Propanediol | 22 | $20,645 |
| GemtesaVibegron | 22 | $14,247 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $7,000 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 13 | $3,612 |
| Omeprazole | 143 | $2,555 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $2,517 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 84 | $2,327 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 98 | $2,200 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 12 | $2,071 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Arexvy | $283 | $79,122119 claims |
| GileadBiktarvy | $33 | $78,40017 claims |
| Lilly USA, LLCMounjaro | $375 | $70,02453 claims |
| Novo NordiskOzempic | $311 | $63,46553 claims |
| PfizerEliquis | $41 | $32,32026 claims |
| AstraZenecaFarxiga | $83 | $20,64522 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $47 | $14,24722 claims |
| AbbVieSynthroid | $342 | $1,74825 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in Sullivan
- Timothy SmithSaint Peters$21.4M
- Craig DietzKansas City$4M
- Michael ReschakSaint Louis$3.1M
- Dima DandachiColumbia$1.2M
- Santosh SharmaKansas City$782K
- Jianbo WangChesterfield$643K
- David PrelutskySaint Louis$575K
- Danish JabbarSaint Louis$510K
- Dubert GuerreroIndependence$369K
- Hany SalamaSaint Louis$279K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.